These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23414404)

  • 1. Developments in virus-like particle-based vaccines for HIV.
    Buonaguro L; Tagliamonte M; Visciano ML; Tornesello ML; Buonaguro FM
    Expert Rev Vaccines; 2013 Feb; 12(2):119-27. PubMed ID: 23414404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in virus-like particle-based vaccines for infectious diseases and cancer.
    Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM
    Expert Rev Vaccines; 2011 Nov; 10(11):1569-83. PubMed ID: 22043956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.
    Berzofsky JA
    Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV/AIDS vaccines: 2007.
    Robinson HL
    Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells.
    Sistigu A; Bracci L; Valentini M; Proietti E; Bona R; Negri DR; Ciccaglione AR; Tritarelli E; Nisini R; Equestre M; Costantino A; Marcantonio C; Santini SM; Lapenta C; Donati S; Tataseo P; Miceli M; Cara A; Federico M
    Vaccine; 2011 Apr; 29(18):3465-75. PubMed ID: 21382480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide-MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development.
    Reguzova AY; Karpenko LI; Mechetina LV; Belyakov IM
    Expert Rev Vaccines; 2015 Jan; 14(1):69-84. PubMed ID: 25373312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A new veil removed from the physiologic mysteries of "HIV control" ].
    Nau JY
    Rev Med Suisse; 2007 Apr; 3(107):1017. PubMed ID: 17526378
    [No Abstract]   [Full Text] [Related]  

  • 9. New research in HIV immunity points way for vaccine.
    Rees J
    Expert Rev Clin Immunol; 2013 May; 9(5):403. PubMed ID: 23772447
    [No Abstract]   [Full Text] [Related]  

  • 10. Virus-like particle-based vaccines against hepatitis C virus infection.
    Bellier B; Klatzmann D
    Expert Rev Vaccines; 2013 Feb; 12(2):143-54. PubMed ID: 23414406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system.
    Tagliamonte M; Visciano ML; Tornesello ML; De Stradis A; Buonaguro FM; Buonaguro L
    Vaccine; 2010 Sep; 28(39):6417-24. PubMed ID: 20678589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimisation of secretion of recombinant HBsAg virus-like particles: Impact on the development of HIV-1/HBV bivalent vaccines.
    Michel M; Lone YC; Centlivre M; Roux P; Wain-Hobson S; Sala M
    Vaccine; 2007 Feb; 25(10):1901-11. PubMed ID: 17005303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introducing a frameshift mutation to the POL sequence of HIV-1 provirus and evaluation of the immunogenic characteristics of the mutated virions (RINNL4-3).
    Zabihollahi R; Sadat SM; Vahabpour R; Salehi M; Azadmanesh K; Siadat SD; Saraji AR; Pouriavali MH; Momen SB; Aghasadeghi MR
    Mol Biol (Mosk); 2012; 46(3):519-24. PubMed ID: 22888641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A strategy of antigen incorporation into exosomes: comparing cross-presentation levels of antigens delivered by engineered exosomes and by lentiviral virus-like particles.
    Lattanzi L; Federico M
    Vaccine; 2012 Nov; 30(50):7229-37. PubMed ID: 23099330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years.
    Lind A; Sommerfelt M; Holmberg JO; Baksaas I; Sørensen B; Kvale D
    Scand J Infect Dis; 2012 Aug; 44(8):566-72. PubMed ID: 22339485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vaccines against HIV].
    Holm-Hansen C
    Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine.
    Kawada M; Tsukamoto T; Yamamoto H; Takeda A; Igarashi H; Watkins DI; Matano T
    J Virol; 2007 May; 81(10):5202-11. PubMed ID: 17344296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus-like particles produced in plants as potential vaccines.
    Scotti N; Rybicki EP
    Expert Rev Vaccines; 2013 Feb; 12(2):211-24. PubMed ID: 23414411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccines against human immunodeficiency virus type 1.
    Estcourt MJ; McMichael AJ; Hanke T
    Immunol Rev; 2004 Jun; 199():144-55. PubMed ID: 15233732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.